Literature DB >> 12006434

Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults.

Hiroshi Tanaka1, Mitsuo Narita, Shin Teramoto, Toyohiro Saikai, Kensuke Oashi, Tomofumi Igarashi, Shosaku Abe.   

Abstract

STUDY
OBJECTIVE: Interleukin (IL)-18 is a proinflammatory cytokine, originally termed interferon (IFN)-gamma-inducing factor, which promotes T-helper type 1 (Th1) cytokine responses. We recently reported that serum IL-18 levels were elevated in children with Mycoplasma pneumoniae pneumonia (MP). In this study, we investigated the contribution of IL-18 to the infection and assessed the Th1 cytokine response to pulmonary involvement in adults.
METHODS: We investigated the clinical course, pulmonary involvement, and serum levels of IL-18, IFN-gamma, IL-12p40, and soluble IL-2 receptor (sIL-2R) in 21 patients with acute-stage MP and in 21 age- and sex-matched control subjects.
RESULTS: Significantly (p < 0.001) increased serum IL-18 (median, 248 pg/mL [range, 89 to 441 pg/mL] vs. median, 126 pg/mL [range, 47 to 217 pg/mL]) and sIL-2R (median, 617 U/mL [range, 410 to 1,032 U/mL] vs. median, 425 U/mL [range, 268 to 601 U/mL]) were found in patients with MP as compared with healthy control subjects, and there was a tendency toward increased serum IFN-gamma and IL-12p40. Circulating IL-18 values had a positive correlation with serum sIL-2R levels (r = 0.62, p = 0.028) and the number of affected pulmonary lobes (sigma = 0.61, p = 0.024), but not with the serum levels of antibodies to M pneumoniae, IFN-gamma, or IL-12p40. Serum IL-18 and sIL-2R values in severe cases were significantly higher (p < 0.03) than those in mild cases. IFN-gamma and sIL-2R levels in four patients with pleural effusion were significantly (p < 0.05) higher than those in the other 17 subjects.
CONCLUSIONS: Serum levels of IL-18 were raised during the acute phase of MP. We suggest IL-18 and Th1 cytokines may play a significant role in the immunopathologic responses in MP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12006434     DOI: 10.1378/chest.121.5.1493

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  45 in total

1.  Evidence of the involvement of caspase-1 under physiologic and pathologic cellular stress during human pregnancy: a link between the inflammasome and parturition.

Authors:  Francesca Gotsch; Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Edi Vaisbuch; Jimmy Espinoza; Juan Pedro Kusanovic; Pooja Mittal; Shali Mazaki-Tovi; Chong Jai Kim; Jung Sun Kim; Samuels Edwin; Chia-Ling Nhan-Chang; Neil Hamill; Laraa Friel; Nandor Gabor Than; Moshe Mazor; Bo Hyun Yoon; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2008-09

2.  Acute respiratory distress syndrome caused by Mycoplasma pneumoniae without elevated pulmonary vascular permeability: a case report.

Authors:  Naoki Takahashi; Tsutomu Shinohara; Rie Oi; Muneyuki Ota; Shinichi Toriumi; Fumitaka Ogushi
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

3.  Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Monica Fonseca-Aten; Christine M Salvatore; Asunción Mejías; Ana M Ríos; Susana Chávez-Bueno; Kathy Katz; Ana M Gómez; George H McCracken; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

Review 4.  Community-acquired pneumonia related to intracellular pathogens.

Authors:  Catia Cillóniz; Antoni Torres; Michael Niederman; Menno van der Eerden; James Chalmers; Tobias Welte; Francesco Blasi
Journal:  Intensive Care Med       Date:  2016-06-08       Impact factor: 17.440

5.  Humoral and cellular immunity in children with Mycoplasma pneumoniae infection: a 1-year prospective study.

Authors:  Iwona Stelmach; Malgorzata Podsiadłowicz-Borzecka; Tomasz Grzelewski; Pawel Majak; Wlodzimierz Stelmach; Joanna Jerzyńska; Marta Popławska; Jaroslaw Dziadek
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

6.  Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan.

Authors:  Mayumi Matsuoka; Mitsuo Narita; Norio Okazaki; Hitomi Ohya; Tsutomu Yamazaki; Kazunobu Ouchi; Isao Suzuki; Tomoaki Andoh; Tsuyoshi Kenri; Yuko Sasaki; Atsuko Horino; Miharu Shintani; Yoshichika Arakawa; Tsuguo Sasaki
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 7.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients.

Authors:  Yasuhiro Kawai; Naoyuki Miyashita; Mika Kubo; Hiroto Akaike; Atsushi Kato; Yoko Nishizawa; Aki Saito; Eisuke Kondo; Hideto Teranishi; Tokio Wakabayashi; Satoko Ogita; Takaaki Tanaka; Kozo Kawasaki; Takashi Nakano; Kihei Terada; Kazunobu Ouchi
Journal:  Antimicrob Agents Chemother       Date:  2013-05-28       Impact factor: 5.191

9.  Three familial cases of drug-resistant Mycoplasma pneumoniae infection.

Authors:  Shintaro Kamizono; Hitomi Ohya; Sadanobu Higuchi; Norio Okazaki; Mitsuo Narita
Journal:  Eur J Pediatr       Date:  2009-11-08       Impact factor: 3.183

10.  The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection.

Authors:  C Tagliabue; C M Salvatore; C Techasaensiri; A Mejias; J P Torres; K Katz; A M Gomez; S Esposito; N Principi; R D Hardy
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.